- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- Wobe-Mugos E, melphalan, prednisone, quality-of-life assessment
- Drug · Procedure
- Lead sponsor
- Medsearch
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 1,888
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Age Related Macular Degeneration
- Interventions
- Ranibizumab, Bevacizumab, Aflibercept, Control Group
- Drug · Other
- Lead sponsor
- East Florida Eye Institute
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Stuart, Florida
- Conditions
- Femoral Fractures, Tibial Fractures
- Interventions
- Retrograde Femoral Nail Advanced, Tibial Nail Advanced
- Device
- Lead sponsor
- DePuy Synthes Products, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 8
- States / cities
- Indianapolis, Indiana • Ann Arbor, Michigan • Columbia, Missouri + 5 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 19
- States / cities
- Greenbrae, California • San Diego, California • Fort Lauderdale, Florida + 16 more
- Conditions
- Leukemia, Myeloma, Myeloproliferative Diseases
- Interventions
- Fludarabine, Melphalan, Alemtuzumab, Stem Cell infusion, Tacrolimus, Mini Methotrexate, G-CSF, Donor Lymphocyte Infusion (DLI), AP1903, Methylprednisolone, Questionnaire
- Drug · Procedure · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Skin Ulcers, Sickle Cell Anemia
- Interventions
- Arginine Butyrate, Standard local care dressing
- Drug · Other
- Lead sponsor
- Susan P. Perrine
- Other
- Eligibility
- 16 Years to 60 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2005
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Smoking Cessation, Second Hand Tobacco Smoke
- Interventions
- Resident counselling, Staff Training
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Stress, Emotional
- Interventions
- ECA System
- Behavioral
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Hyperpolarized Xenon-129 MRI (Experimental), Radioactive Xenon-133 scintigraphy (Active Comparator)
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Acute Respiratory Infection
- Interventions
- Integrated clinical prediction rule (iCPR) system (iCPR)
- Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- New York, New York • Salt Lake City, Utah • Madison, Wisconsin
- Conditions
- Diabetic Foot, Diabetic Foot Ulcer, Ulcer Foot
- Interventions
- Human Autologous Homologous Skin Construct, Additional Outer Dressing Applicaiton, Offloading, Fibracol Wound Dressing
- Other
- Lead sponsor
- PolarityTE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Martinsville, Virginia
- Conditions
- Heart Failure
- Interventions
- Iobenguane I -123 Injection, Implantable Cardioverter Defibrillator, Thyroid blocking
- Drug · Device
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Bakersfield, California • La Mesa, California + 24 more
- Conditions
- Asthma
- Interventions
- Fluticasone propionate/salmeterol (FS), Albuterol, Standard of Care Asthma Medication, Standard of Care Rescue Medication
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 427 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 37 more
- Conditions
- Multiple Sclerosis
- Interventions
- Discontinuation of disease modifying therapy, Standard of Care
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 14 more
- Conditions
- Opiate Addiction
- Interventions
- Brief Negotiation Interview (BNI), Buprenorphine Initiation
- Behavioral · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- Nephrotic Syndrome
- Interventions
- Prednisolone
- Drug
- Lead sponsor
- All India Institute of Medical Sciences
- Other
- Eligibility
- 1 Year to 4 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Stanford, California • Ann Arbor, Michigan + 1 more
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Colorectal Carcinoma, Unresectable Rectal Adenocarcinoma
- Interventions
- Panitumumab, Quality-of-Life Assessment, Questionnaire Administration, Regorafenib, Trifluridine and Tipiracil Hydrochloride
- Biological · Other · Drug
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 11 more
- Conditions
- Traumatic Brain Injury
- Interventions
- Progesterone, Placebo
- Drug
- Lead sponsor
- David Wright
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 882 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tuscon, Arizona + 26 more
- Conditions
- Infections Resistant to Multiple Drugs, Bacterial Infections
- Interventions
- Standard of Care
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 6,496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Transient Ischemic Attack, Stroke, Atrial Fibrillation
- Interventions
- Apixaban, Warfarin
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 5
- States / cities
- Torrance, California • St. Petersburg, Florida • Tampa, Florida + 1 more
- Conditions
- High Risk Hematological Malignancy, Cord Blood Transplant
- Interventions
- ECT-001-CB (UM171-Expanded Cord Blood Transplant)
- Biological
- Lead sponsor
- ExCellThera inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Seattle, Washington
- Conditions
- Hyperlipidemia and Mixed Dyslipidemia
- Interventions
- Evolocumab, Standard of Care
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 3,681 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more
- Conditions
- Adhesive Capsulitis of the Shoulder, Frozen Shoulder
- Interventions
- Hormone Replacement Therapy (HRT), Corticosteroid and 1%lidocain, physical therapy
- Drug · Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Tuberculosis
- Interventions
- rifapentine, rifapentine and moxifloxacin, control
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 12 Years and older
- Enrollment
- 2,516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 5
- States / cities
- San Francisco, California • New York, New York • Fort Worth, Texas + 2 more